Based on first in class nanomotion technology platform, our rapid AST saves lives by finding the right antibiotic on time and reduces spreading of antibiotic resistance

TOP 100 Swiss Startup Award has become a benchmark in Switzerland’s startup ecosystem. The award show connects the most promising Swiss startups with Swiss and international investors, executives, and journalists. The invitation-only Award Night has become the most awaited start-up event of the year. We are honored to announce that Resistell has once again secured a coveted spot in the Top 10 of the TOP 100 Swiss Startup Award! For the third time, our dedication to innovation has been recognized by a panel of 100 leading investors and industry experts. This prestigious award is not just a recognition of our hard work, but also a testament to the incredible team behind Resistell and the invaluable support from our partners and stakeholders. We are thrilled to be part of Switzerland’s dynamic startup ecosystem, and we remain committed to pushing the boundaries of science and technology to combat antibiotic resistance and improve patient care.

Scientists from EPFL and Vrije Universiteit Brussel have been working for several years on a new nanomotion based method to detect bacterial sensitivity to antibiotics. In essence, it involves “watching the bacteria dance”. Joining Stéphane Gabioud and journalist, Cécile Guérin, on Swiss radio show CQFD to discuss this new method is Professor Gilbert Greub MD-PhD, Chief Physician of Diagnostic Laboratories at the University Hospital of Vaud (CHUV) and scientific advisor to Resistell, the company commercializing this novel detection method.

The @Innovative Medicines for Tuberculosis (iM4TB) foundation, a Swiss non-profit fighting tuberculosis (TB), is pleased to announce a new partnership with @Resistell. The partners will harness Resistell’s proprietary Phenotech technology to further investigate iM4TB’s TB drug candidate, macozinone (PBTZ169).

Resistell, a leader in phenotypic nanomotion technology for measuring living cells, is proud to announce the launch of its next international, multisite clinical study, PHENOTECH-1.

Resistell AG, a leader in phenotypic nanomotion technology for measuring living cells, has taken another major step to achieving its vision by closing a first tranche of its series B financing round raising CHF 8.5M from new and existing investors.

Meet Resistell team at Bio Japan 2022 at Swisstech booth. Learn about World’s fastest Antibiotic Susceptibility Test based on the first in class nanomotion technology platform!

To celebrate its 15th anniversary Venture Kick issued movie series about the impact VK alumni have on solving the most pressing global issues. See Resistell in an episode about antibiotic resistance. Thank you for featuring us!

Resistell, a TOP10 Swiss Start-up addressing the problem of speed in the diagnostics of antibiotic resistance, is pleased to announce they have initiated a research project to assess the applicability of Resistell’s antibiotic susceptibility test (AST) to a novel antibiotic. The project is funded by an independent grant from Pfizer AG.

Run in close collaboration with the microbiologists and infectious diseases specialists at the Lausanne University Hospital (CHUV) in Switzerland, the goal of the ongoing clinical study is to assess the sensitivity, specificity, accuracy and time to result of Resistell AST compared to the gold standard methods used at CHUV, namely Kirby-Bauer disc diffusion test and automated Vitek2 system® (bioMérieux). The study focuses on patients admitted to CHUV with bacteremia or sepsis due to Gram-negative bacteria.

Resistell is proud to be a part of SPEARHEAD project which launches to address the silent pandemic of antimicrobial resistance (AMR).